Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. J of Skin [Internet]. 2024 Nov. 18 [cited 2026 May 2];8(6):s490. Available from: https://skin.dermsquared.com/skin/article/view/3136